Literature DB >> 25547827

Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas.

Gabriella Szentkúti1, Kornél Dános, Diána Brauswetter, Gergő Kiszner, Tibor Krenács, László Csákó, Gábor Répássy, László Tamás.   

Abstract

Head and neck squamous cell carcinomas (HNSCC) show diverse clinicopathological features and are mostly linked with poor outcome. In this study, we tested if the expression of tumor growth, cell cycle and basement membrane anchorage related biomarkers allow prognostic and clinicopathological stratification of HNSCC. Archived HNSCC samples from 226 patients included into tissue microarrays (TMA) were tested using immunohistochemistry. Histopathological evaluation and the analysis of immunostaining for EGFR, Ki67, p53, p16(ink4) and Collagen XVII proteins were carried out in digital whole slides. Statistical evaluation was carried out using Pearson's Chi-square test and Kaplan-Meier survival analysis. In the tested cohort, hypopharyngeal cancers had the least favorable, and glottic cancers had the most favorable prognosis. High Ki67 positive tumor cell fractions were associated with significantly worse prognosis and elevated rate of lymph node metastasis. Both Ki67 and EGFR expression correlated significantly with the tumor localization. Ki67 index was the highest in the hypopharyngeal region and it proved to be the lowest in the glottic region. EGFR expression was the highest in the oral cavity and the lowest in the glottic region. The survival rate of patients with p16(ink4)-negative cancer was significantly lower than of those with p16(ink4)-positive disease. A significant inverse correlation was found between histological grade and the prognosis of HNSCC. Our data support that elevated Ki67 positive proliferating cell fractions contribute to the unfavorable prognosis of hypopharyngeal cancers, while glottic cancers have the most favorable prognosis because of the lowest Ki67 expression rate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25547827     DOI: 10.1007/s12253-014-9869-4

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

1.  Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas.

Authors:  Balázs Szabó; Györgyi A Nelhubel; Adél Kárpáti; István Kenessey; Balázs Jóri; Csilla Székely; István Peták; Gábor Lotz; Zita Hegedus; Balázs Hegedus; Tibor Füle; Balázs Döme; József Tímár; József Tóvári
Journal:  Oral Oncol       Date:  2011-04-16       Impact factor: 5.337

2.  Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67.

Authors:  M Matsumoto; K Komiyama; M Okaue; Y Shimoyama; K Iwakami; S Namaki; H Tanaka; I Moro; H Sato
Journal:  J Oral Sci       Date:  1999-06       Impact factor: 1.556

3.  Differential biomarker expression in head and neck cancer correlates with anatomical localization.

Authors:  László Tamás; Gabriella Szentkúti; Mónika Eros; Kornél Dános; Diána Brauswetter; Béla Szende; Ivett Zsákovics; Tibor Krenács
Journal:  Pathol Oncol Res       Date:  2011-04-13       Impact factor: 3.201

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Prognostic significance of P53 histochemistry and DNA histogram parameters in head and neck malignancies.

Authors:  L Tamás; H Kraxner; L Mechtler; G Répássy; O Ribári; A Hirschberg; G Szentkúti; B Járay; Z Szentirmay
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

6.  Retinoblastoma protein function and p16INK4a expression in actinic keratosis, squamous cell carcinoma in situ and invasive squamous cell carcinoma of the skin and links between p16INK4a expression and infiltrative behavior.

Authors:  Kristina Nilsson; Sofie Svensson; Göran Landberg
Journal:  Mod Pathol       Date:  2004-12       Impact factor: 7.842

7.  Has the cellular proliferation marker Ki67 any clinical relevance in squamous cell carcinoma of the head and neck?

Authors:  N J Roland; A W Caslin; G L Bowie; A S Jones
Journal:  Clin Otolaryngol Allied Sci       Date:  1994-02

8.  Frequent p53 mutations in head and neck cancer.

Authors:  K D Somers; M A Merrick; M E Lopez; L S Incognito; G L Schechter; G Casey
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

9.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

Review 10.  Staging and prognosis in head and neck cancer.

Authors:  Marc P van der Schroeff; Robert J Baatenburg de Jong
Journal:  Oral Oncol       Date:  2008-08-19       Impact factor: 5.337

View more
  14 in total

Review 1.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

2.  Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.

Authors:  Toshiya Maebayashi; Naoya Ishibashi; Takuya Aizawa; Masakuni Sakaguchi; Tsutomu Saito; Jiro Kawamori; Yoshiaki Tanaka; Yukari Hirotani; Taku Homma
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-12       Impact factor: 2.503

3.  Loss of E-Cadherin Expression Correlates With Ki-67 in Head and Neck Squamous Cell Carcinoma.

Authors:  Cristina Stefania Dumitru; Amalia Raluca Ceausu; Serban Comsa; Marius Raica
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma.

Authors:  Masao Takenobu; Mitsuhiko Osaki; Kazunori Fujiwara; Takahiro Fukuhara; Hiroya Kitano; Hiroyuki Kugoh; Futoshi Okada
Journal:  Mol Clin Oncol       Date:  2016-04-28

5.  Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.

Authors:  Diána Brauswetter; Kornél Dános; Bianka Gurbi; Éva Fruzsina Félegyházi; Ede Birtalan; Nóra Meggyesházi; Tibor Krenács; László Tamás; István Peták
Journal:  Virchows Arch       Date:  2016-01-29       Impact factor: 4.064

6.  Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer.

Authors:  Li-Hsuen Chen; Dai-Wei Liu; Junn-Liang Chang; Peir-Rong Chen; Lee-Ping Hsu; Hon-Yi Lin; Yu-Fu Chou; Chia-Fong Lee; Miao-Chun Yang; Yu-Hsuan Wen; Wen-Lin Hsu; Ching-Feng Weng
Journal:  J Exp Clin Cancer Res       Date:  2015-02-24

7.  Lipid nanoemulsions and liposomes improve photodynamic treatment efficacy and tolerance in CAL-33 tumor bearing nude mice.

Authors:  Doris Hinger; Susanna Gräfe; Fabrice Navarro; Bernhard Spingler; Devaraj Pandiarajan; Heinrich Walt; Anne-Claude Couffin; Caroline Maake
Journal:  J Nanobiotechnology       Date:  2016-10-03       Impact factor: 10.435

Review 8.  Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma.

Authors:  Paolo Bossi; Carlo Resteghini; Nicholas Paielli; Lisa Licitra; Silvana Pilotti; Federica Perrone
Journal:  Oncotarget       Date:  2016-11-08

9.  Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer.

Authors:  Garazi Serna; Sara Simonetti; Roberta Fasani; Francesca Pagliuca; Xavier Guardia; Paqui Gallego; Jose Jimenez; Vicente Peg; Cristina Saura; Serenella Eppenberger-Castori; Santiago Ramon Y Cajal; Luigi Terracciano; Paolo Nuciforo
Journal:  Breast       Date:  2020-07-13       Impact factor: 4.380

10.  Associations between FDG-PET and Ki 67-index in head and neck cancer: A meta-analysis.

Authors:  Hans-Jonas Meyer; Peter Gundermann; Alexey Surov
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.